Search

Your search keyword '"Ahmed Idbaih"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Ahmed Idbaih" Remove constraint Author: "Ahmed Idbaih" Publisher hal ccsd Remove constraint Publisher: hal ccsd
47 results on '"Ahmed Idbaih"'

Search Results

1. Challenges in glioblastoma research: focus on the tumor microenvironment

2. Glioblastoma cell motility depends on enhanced oxidative stress coupled with mobilization of a sulfurtransferase

3. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study

4. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial

5. PAK3 is a key signature gene of the glioma proneural subtype and affects its proliferation, differentiation and growth

6. BRAF mutation in overlapping forms of Erdheim-Chester and Rosai-Dorfman diseases: A unique case restricted to the central nervous system

7. A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin

8. Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models

9. SARS-CoV-2 infection in patients with primary central nervous system lymphoma

10. Leptomeningeal spread in glioblastoma: diagnostic and therapeutic challenges

11. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives

12. Central nervous system involvement in Erdheim-Chester disease: An observational cohort study

13. Biodegraded magnetosomes with reduced size and heating power maintain a persistent activity against intracranial U87-Luc mouse GBM tumors

14. EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma

15. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas

16. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas

17. Endocrine manifestations in a cohort of 63 adulthood and childhood onset patients with Langerhans cell histiocytosis

18. FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas

19. IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas

20. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome

21. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma

22. Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model

23. Development of non-pyrogenic magnetosome minerals coated with poly- l -lysine leading to full disappearance of intracranial U87-Luc tumors in 100% of treated mice using magnetic hyperthermia

24. Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field

25. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

26. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort

27. Neurohistiocytose langerhansienne

28. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma

29. Apport des données moléculaires dans la prise en charge médicale des patients souffrant de tumeur cérébrale primitive

30. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations

31. An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas

32. Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy

33. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas

34. Correction: ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target

35. An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients

36. Genomic changes in progression of low-grade gliomas

37. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas

38. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors

39. Mutational analysis of Rac2 in gliomas

40. No association of MDM2 SNP309 with risk of glioblastoma and prognosis

41. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors

42. Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas

43. Two types of chromosome 1p losses with opposite significance in gliomas

44. Association of Clinical, Biological, and Brain Magnetic Resonance Imaging Findings With Electroencephalographic Findings for Patients With COVID-19

45. Mechanisms and Therapeutic Implications of Hypermutation in Gliomas

46. Potentialisation des chimiothérapies dans le traitement du glioblastome : étude des transporteurs ABC et ouverture de la barrière hémato-encéphalique par ultrasons

47. Potentiation of Chemotherapies in the Treatment of Glioblastoma : Study of ABC Transporters and Opening of the Blood-Brain Barrier by Ultrasound

Catalog

Books, media, physical & digital resources